UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3137900 (State or other jurisdiction of incorporation or organization) 10 North High Street, Suite 200 West Chester, PA 19380 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification No.) Registrant's telephone number, including area code: (484) 453-3300 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3137900 (State or other juri ...

Company Overview June 2020 Copyright © 2020 Verrica Pharmaceuticals. All rights reserved. DISCLAIMER Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica's own internal estimates and research. While Verrica believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no re ...

Investment Highlights - Verrica addresses two large unmet needs in dermatology: molluscum contagiosum with a prevalence of approximately 6 million in the US, and common warts with a prevalence of approximately 22 million in the US[12, 161] - Ycanth™ (VP-102) has a PDUFA goal date of July 13, 2020, for the treatment of molluscum contagiosum[12, 157, 161] - Phase 3 trials for Ycanth™ (VP-102) in molluscum contagiosum achieved statistical significance for primary endpoints with a p-value < 00001 in both pivotal trials[12, 161] - VP-102 achieved positive topline Phase 2 results in common warts, demonstrating complete clearance of all treatable warts at Week 12 (Day 84)[12, 161] Clinical Trial Results - In Phase 3 molluscum trials, 50% of patients treated with VP-102 achieved complete clearance of molluscum lesions at Day 84, compared to 168% in the vehicle group (P < 00001)[71] - Phase 3 molluscum trials also demonstrated a statistically significant efficacy on percent reduction of lesions, with VP-102 showing a -76% change from baseline to Day 84 compared to -59% for the vehicle group (P < 00001)[74] - In the COVE-1 study for common warts, VP-102 demonstrated clinically meaningful efficacy on the primary endpoint of complete clearance, with 40% to 514% clearance depending on the cohort at EOS/EOT (Day 84)[121] Commercial Opportunity - In the US, approximately 6 million people have molluscum, with approximately 1 million diagnosed annually[12, 21, 84, 161] - Approximately 87% of physicians reported they would use Ycanth™ (VP-102) if the cost of the drug was covered[89] - Initial payer research suggests a favorable reimbursement landscape for Ycanth™ (VP-102), with interviewed payer organizations and plans covering a total of 105 million commercial & Medicaid lives[93, 97]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorpo ...

Company Overview March 2020 Copyright © 2020 Verrica Pharmaceuticals. All rights reserved. DISCLAIMER Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica's own internal estimates and research. While Verrica believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no r ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38529 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware 46-3137900 | | | | | --- | --- | --- | --- | | (State or other juri ...

Company Overview March 2020 Copyright © 2020 Verrica Pharmaceuticals. All rights reserved. DISCLAIMER Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica's own internal estimates and research. While Verrica believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no r ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3137900 (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3137900 (State or other juri ...